Olema Pharmaceuticals (OLMA) Retained Earnings (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Retained Earnings of $1.1 billion for Q1 2026, up 33.36% year-over-year from $848.5 million in Q1 2025, and up 5.22% quarter-over-quarter from $1.1 billion in Q4 2025.
Olema Pharmaceuticals (OLMA) Retained Earnings (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Retained Earnings for 7 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 33.36% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 33.36% YoY), while the FY2025 annual figure was $1.1 billion, up 347.18% from the prior year.
- Retained Earnings advanced to $1.1 billion in Q1 2026 per OLMA's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $1.1 billion in Q1 2026 and bottomed at -$509.3 million in Q2 2025.
- Historically, Retained Earnings has averaged $257.0 million across 5 years, with a median of $393.9 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 2848357.14% — and 2024, when it tumbled 125490.78%.
- Olema Pharmaceuticals' Retained Earnings stood at -$209.0 million in 2022, then jumped by 100.17% to $347000.0 in 2023, then sank by 125490.78% to -$435.1 million in 2024, then jumped by 347.18% to $1.1 billion in 2025, then advanced by 5.22% to $1.1 billion in 2026.
- Business Quant data shows OLMA's Retained Earnings at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $858.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 1.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.15 Bn |
| Mar 31, 2026 | 1.13 Bn |
| Dec 31, 2025 | 1.08 Bn |
| Sep 30, 2025 | 858.45 Mn |
| Jun 30, 2025 | -509.28 Mn |
| Mar 31, 2025 | 848.52 Mn |
| Dec 31, 2024 | -435.11 Mn |
| Sep 30, 2024 | 599.98 Mn |
| Jun 30, 2024 | 594.26 Mn |
| Mar 31, 2024 | -336.60 Mn |
| Dec 31, 2023 | 347,000.00 |
| Sep 30, 2023 | -278.86 Mn |
| Jun 30, 2023 | 419.46 Mn |
| Mar 31, 2023 | -978,000.00 |
| Dec 31, 2022 | -208.98 Mn |
| Sep 30, 2022 | -182.80 Mn |
| Jun 30, 2022 | 398.76 Mn |
| Mar 31, 2022 | 393.93 Mn |
| Dec 31, 2021 | 388.90 Mn |
| Sep 30, 2021 | -82.55 Mn |